Alphatec Holdings, Inc. (ATEC)
| Market Cap | 1.28B -55.2% |
| Revenue (ttm) | 839.72M +15.3% |
| Net Income | -86.89M |
| EPS | -0.56 |
| Shares Out | 155.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,144,402 |
| Open | 7.45 |
| Previous Close | 7.47 |
| Day's Range | 7.45 - 8.34 |
| 52-Week Range | 6.81 - 23.29 |
| Beta | 0.87 |
| Analysts | Buy |
| Price Target | 13.29 (+60.51%) |
| Earnings Date | Oct 29, 2026 |
About ATEC
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-o... [Read more]
Financial Performance
In 2025, Alphatec Holdings's revenue was $764.16 million, an increase of 24.95% compared to the previous year's $611.56 million. Losses were -$143.36 million, -11.57% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for ATEC stock is "Buy." The 12-month stock price target is $13.29, which is an increase of 60.51% from the latest price.
News
ATEC Investors Have Opportunity to Join Alphatec Holdings, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $ATEC--ATEC Investors Have Opportunity to Join Alphatec Holdings, Inc. Fraud Investigation with SBS Law.
UBS downgrades Alphatec to Neutral, has less conviction in growth
UBS analyst Patrick Wood downgraded Alphatec (ATEC) to Neutral from Buy with a price target of $8.50, down from $15. While Alphatech remains “one of the more innovative players in…
Alphatec downgraded to Neutral from Buy at UBS
UBS downgraded Alphatec (ATEC) to Neutral from Buy with a price target of $8.50, down from $15.
ATEC SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Alphatec Holdings
ATEC shares fell sharply after Alphatec Holdings cut its full-year 2026 revenue outlook to approximately $862 million, citing biologics, thoracolumbar, and international supply pressures. SueWallSt no...
Alphatec price target lowered to $15 from $16 at JPMorgan
JPMorgan lowered the firm’s price target on Alphatec (ATEC) to $15 from $16 and keeps an Overweight rating on the shares.
Alphatec Plunges 32%. A Bone-Graft Slump Hits the Spine Specialist's Stock.
Alphatec slashes its full-year outlook as fewer surgeons have purchased its add-on bone-graft products used for spinal fusion.
Alphatec price target lowered to $14 from $15 at Lake Street
Lake Street lowered the firm’s price target on Alphatec (ATEC) to $14 from $15 and keeps a Buy rating on the shares after “a mixed quarter.” Shares “will have a…
Alphatec price target lowered to $10 from $13 at TD Cowen
TD Cowen analyst Mathew Blackman lowered the firm’s price target on Alphatec (ATEC) to $10 from $13 and keeps a Buy rating on the shares. The firm said 3Q disappointed…
Alphatec price target lowered to $12 from $14 at Needham
Needham lowered the firm’s price target on Alphatec (ATEC) to $12 from $14 and keeps a Buy rating on the shares. The firm cites the company’s miss on Q3 revenue…
Alphatec price target lowered to $11 from $13 at Stifel
Stifel lowered the firm’s price target on Alphatec (ATEC) to $11 from $13 and keeps a Buy rating on the shares.
Alphatec price target lowered to $16 from $19 at Canaccord
Canaccord lowered the firm’s price target on Alphatec (ATEC) to $16 from $19 and keeps a Buy rating on the shares. The firm said they posted a soft Q3 with…
Alphatec downgraded to Market Perform from Outperform at BMO Capital
BMO Capital analyst Vik Chopra downgraded Alphatec (ATEC) to Market Perform from Outperform with a price target of $8, down from $12, post the Q3 report. The company’s biologics attachment…
Alphatec down 27% at $8.26 after Q3 earnings miss and guidance cut
16:42 EDT Alphatec (ATEC) down 27% at $8.26 after Q3 earnings miss and guidance cut
Alphatec Holdings Earnings Call Transcript: Q3 2026
Q3 revenue rose 13% to $221M and Adjusted EBITDA reached $38M, but lower biologics attachment, softer thoracolumbar volumes and uneven EOS installations drove reduced FY guidance. FY revenue is now expected at ~$862M, with a 16% Adjusted EBITDA margin.
Alphatec Holdings Earnings release: Q3 2026
Alphatec Holdings released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Alphatec Holdings Slides: Q3 2026
Alphatec Holdings has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Alphatec Holdings Quarterly report: Q3 2026
Alphatec Holdings has published its Q3 2026 quarterly earnings report on October 29, 2026.
ATEC Reports Third Quarter Financial Results
CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced ...
ATEC to Report Third Quarter 2026 Financial Results on October 29, 2026
CARLSBAD, Calif--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will re...
ATEC Appoints Tommy Carls Executive Vice President, Data Intelligence and Strategy
CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced ...
Alphatec CEO buys $1.01M in common stock
In a regulatory filing, Alphatec (ATEC) disclosed that its CEO Patrick Miles bought 115K shares of common stock on September 10 in a total transaction size of $1.01M. Shares are…
Alphatec Holdings Transcript: Wells Fargo 21st Annual Healthcare Conference
Procedural volumes and surgeon adoption remain strong, supporting robust revenue and EBITDA growth targets through 2027. Product innovation in Valence, EOS Insight, and biologics, along with disciplined cost management, underpin confidence in meeting long-term financial goals.
Alphatec price target raised to $16 from $15 at UBS
UBS raised the firm’s price target on Alphatec (ATEC) to $16 from $15 and keeps a Buy rating on the shares.
Alphatec price target raised to $13 from $11 at TD Cowen
TD Cowen raised the firm’s price target on Alphatec (ATEC) to $13 from $11 and keeps a Buy rating on the shares. The firm said . 2Q was much better…
Alphatec price target lowered to $19 from $23 at Canaccord
Canaccord lowered the firm’s price target on Alphatec (ATEC) to $19 from $23 and keeps a Buy rating on the shares. The firm said they posted a solid Q2 with…